Truly amazing some of these conclusions.
Amazing, how CYP already saw the potential of iPSC as starting material before FujiFilm saw it:
https://www.asx.com.au/asxpdf/20140918/pdf/42s92zp5qmrdn3.pdf
Yes, September 2014.
Who has followed since?
FujiFilm in 2015,
Roche in 2015,
Takeda in 2018,
JointVenture with Bayer in 2019,
Lonza in 2020 &
JointVenture with Bluerock in 2021.
Just to name a few.
Out of all of them, which company has an iPSC derived therapy currently in a P3 trial?
Any other company using iPSC cells (starting material or therapy) in a P3 trial?
Given that there is still a lack of standarization when it comes to iPSCs, would you deem it a good sign that global leaders (and i take it you deem Lonza being one) adapt FCDI's iPSC standards and other heavyweights start using FCDI's iPSC lines?
FCDI/FF is using the clinical result of our P1 to advertise their iPSC starting material, given that CYP has already taken it through a P1 trial:
https://www.sciencemagazinedigital....ilePagedReplica.action?pm=2&folio=IFC#pg2
FCDI is also using CYP references in their presentations:
"Leading the field of breakthrough cellular therapies using induced pluripotent stem cells (iPSCs)
- Phase II - Graft Versus Host Disease with Cynata Therapeutics"
Feel free to watch the presentation:
So... has FF ever said this about CYP - yes. I could go on with the quotes, but the above I believe should suffice.
I'm somewhat surprised that you only mention diabetes as Novo Nordisk's field of interest:
https://www.novonordisk.com/science-and-technology/cell-therapy.html
I also see CHF...
What could be of particular interest further down the track is the government funded work of Dr Lim:
https://www.biospace.com/article/-1...nata-s-mscs-as-a-treatment-for-heart-disease/
Dr Lim has also tested a similar device in diabetes.
Wouldn't that be something...
Now that NN starts getting comfortable with the iPSC starting material, who knows, maybe we will post pictures on here soon of Ross heading to Tafe to pick-up some Danish catch-phrases/words:
https://www.techdico.com/translation/english-danish/bulldozer.html
https://www.techdico.com/translation/english-danish/shovel.html
I always have to chuckle when people going on about CYP's pre-clinical data in sheep, rats, mice etc. all while using Fetal Bovine Serum in their clinical trials. Perhaps one might want to check the "ingredients".
Fetal bovine serum (FBS) is the liquid fraction of clotted blood from fetal calves, depleted of cells, fibrin and clotting factors, but containing a large number of nutritional and macromolecular factors essential for cell growth. Bovine serum albumin is the major component of FBS. Growth factors in FBS are essential for the maintenance and growth of cultured cells [1, 2]. FBS also contains a variety of small molecules like amino acids, sugars, lipids, and hormones.
https://www.labome.com/method/Fetal-Bovine-Serum.html
Fetal bovine serum (FBS) is derived from the blood drawn from a bovine fetus via a closed system of collection at the slaughterhouse. Fetal bovine serum is the most widely used serum-supplement for the in vitro cell culture of eukaryotic cells. This is due to it having a very low level of antibodies and containing more growth factors, allowing for versatility in many different cell culture applications.
https://en.wikipedia.org/wiki/Fetal_bovine_serum
(20min delay)